ArticleLeukemia2024

Long-term outcomes after upfront second-generation tyrosine kinase inhibitors for chronic myeloid leukemia: managing intolerance and resistance.

Simone Claudiani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.